The year 2020 is the final year of China's major science and technology project of "major new drug discovery and development" (officially referred to as the new drug project). Learned, as a major measure for national science and technology development and promote Chinese medicine important driver of innovation, our country started in 2008 since the implementation of the "major drug discovery" science and technology major projects, there are a number of "major drug discovery" special achievements, especially high-tech products to achieve good performance and result, Chinese traditional medicine for innovation and development of traditional Chinese medicine in China's a major painted.
 

　　 Among them, Heilongjiang ZBD Pharmaceutical Co., Ltd. participated in the major scientific and technological project of "Major New Drug Creation" led by Beijing Children's Hospital Affiliated to Capital Medical University: a sub-project in the research and development of children's drug varieties and key technologies -- research on the key technologies and industrialization of traditional Chinese medicine preparations for children. The variety participating in the study is ZBD ® Compound Qinlan Oral Liquid. The clinical study is led by Dongfang Hospital of Beijing University of Chinese Medicine, and the clinical study has been completed.
 

　　 In this study, the dose-effectiveness and safety of Compound Qinlan Oral Liquid in the treatment of children with acute upper respiratory tract infection (wind-heat cold syndrome) were evaluated by the method of randomized control, double-blind, dose exploration and multi-center clinical study. The 3-day cure rate of placebo group, high dose group and low dose group was 47.22%, 94.29% and 79.41%(PPS), respectively.The results showed that Compound Qinlan Oral Liquid had definite efficacy and good safety in the treatment of 6-12 year old children with acute upper respiratory tract infection (wind-heat cold syndrome). The high dose of compound Qinlan Oral Liquid could significantly improve the symptoms of nasal congestion, while the low dose of compound Qinlan Oral Liquid showed good effect in improving the symptoms of turffy nose and thirst.The multi-center randomized controlled clinical study on Compound Qinlan Oral Liquid in the treatment of children with acute upper respiratory tract infection (wind-heat cold syndrome) has been completed and will be published in national core academic journals in the next step.
 

　　 According to the query data of China Pharmaceutical Industry Information Center, ZBD Pharmaceutical Co., Ltd. is the only one of the sample hospitals selling Compound Qinlan Oral Liquid in the whole country during 2016‐2018, taking the leading position in the market. This product is an antiviral traditional Chinese medicine product exclusively developed by ZBD Pharmaceutical Co., Ltd., with a sales growth rate of nearly 65% in 2020. The good performance in the research on the varieties and key technologies of children's drugs will be more conducive to the in-depth expansion of the market share of Compound Qinlan Oral Liquid for children's drugs, and the sales of this product will continue to be promising in 2021.
 

　　 Apart from the above research results, China institute of traditional Chinese medicine academy of sciences conducted in February 2020, the compound Qin LAN oral liquid on coronavirus pneumonia epidemic poison attack card therapeutic research, through the experiment data prove that the compound Qin orchid liquid active ingredients can will be coronavirus infection symptoms have remedial effect, "journal of Chinese herbal medicine published titled" compound Qin LAN oral liquid on coronavirus pneumonia epidemic poison attack the therapeutic effect of pulmonary syndrome "academic research papers. 
 

　　 It is understood that in addition to the compound Qin LAN oral liquid, in traditional Chinese medicine research and development, treasured island continues to invest a large amount of money and energy, joint well-known universities and research institutions across the country, the development of some existing mature products secondary development work, accumulate a batch with injection of blood and blood clots, capsules, and compound Qin oral liquid has unique technology represented by core competitiveness of the varieties. At the same time, through product acquisition and screening of domestic exclusive varieties and medical insurance varieties, ZBD has enriched the existing pipeline of traditional Chinese medicine products, and accelerated the promotion of new traditional Chinese medicine products such as hospital preparations and health products. 
 

　　 In the future, treasured island pharmaceutical industry will continue to take advantage of the characteristics of TCM, create series of varieties of traditional Chinese medicines with international leading level, promoting the value of traditional Chinese medicine industry and the status, and to sustainable, steady development of traditional Chinese medicine to promote science and technology the establishment of the pattern of traditional Chinese medicine industry, to the health of the people to provide more quality products and services.